Vanda Pharmaceuticals
VNDAVNDA · Stock Price
Historical price data
Overview
Vanda Pharmaceuticals is a publicly traded biopharma company with a mission to 'innovate in the service of people's pursuit of happiness' by developing targeted therapies for CNS and sleep disorders. Its core strategy integrates genetics and genomics into all stages of drug development to enhance clinical trial success and commercial positioning. Key achievements include the FDA approvals of Fanapt® for schizophrenia and Hetlioz® for Non-24, with recent milestones including the 2026 approval of BYSANTI™ and a landmark FDA hearing for Hetlioz® in Jet Lag Disorder.
Technology Platform
Integrated genetics and pharmacogenetics platform applied to drug development for patient stratification, optimized clinical trials, and precision commercialization.
Pipeline
77| Drug | Indication | Stage | Watch |
|---|---|---|---|
| tasimelteon 20 mg capsule + tasimelteon 2 mg I.V. | Non-24-Hour-Sleep-Wake Disorder | Approved | |
| Iloperidone | Schizophrenia | Approved | |
| Imsidolimab | Generalized Pustular Psoriasis | Phase 3 | |
| Iloperidone + Placebo | Schizophrenia | Phase 3 | |
| Iloperidone + Ziprasidone + Placebo | Schizophrenia | Phase 3 |
Funding History
3FDA Approved Drugs
4Opportunities
Risk Factors
Competitive Landscape
Vanda competes in niche, high-unmet-need markets (e.g., Non-24) with limited direct competition but faces giants in crowded CNS spaces like schizophrenia. Its differentiation relies on pharmacogenetic targeting and novel mechanisms, but commercial scale is a challenge against larger, well-resourced competitors.
Company Timeline
Founded in Washington DC, United States
Series A: $10.0M
Series B: $20.0M
IPO — $50.0M
FDA Approval: HETLIOZ
FDA Approval: HETLIOZ LQ